Feedback

Small Cell Lung Cancer

Joshua K. Sabari, Natasha B. Leighl, Frances A. Shepherd, Charles M. Rudin
Small Cell Lung Cancer is a topic covered in the Pearson's General Thoracic.

To view the entire topic, please or .

STS Cardiothoracic Surgery E-Book from The Society of Thoracic Surgeons provides expert guidance for Cardiac and Thoracic Surgery. Sections include Pearson’s General Thoracic, Esphageal, Adult Cardiac, and Pediatric and Congenital Cardiac Surgery. Explore these free sample topics:

-- The first section of this topic is shown below --

Key Point

  • Small cell lung cancer (SCLC) represents approximately 15% of lung cancer cases.
  • SCLC is generally divided into two functional stages, limited (LS-SCLC) and extensive (ES-SCLC). Limited-stage is disease confined to a single radiation port – within one hemithorax with or without involvement of lymph nodes in the mediastinum. Extensive stage is disease beyond those confines, generally outside the chest or with contralateral chest involvement. LS-SCLC median overall survival is 20 months, 1-year survival 60%, 5-year survival 20%. ES-SCLC median overall survival is 13 months, 1-year survival 54%, 5-year survival 1%. In the 8th edition of the AJCC staging manual, TNM staging is now applied to small cell lung cancer but most clinicians continue to use the old system.
  • The standard treatment for LS-SCLC is chemotherapy (e.g. etoposide/platinum) and concurrent chest radiotherapy, followed by PCI in responding patients; this is associated with a long-term survival rate of 15% to 20%. Stage I(small tumor, node-negative) cases can be approached with surgical resection followed by adjuvant systemic chemotherapy with four cycles of cisplatin and etoposide.
  • Standard therapy for ES-SCLC is systemic chemotherapy (e.g., four cycles of etoposide/platinum) with immunotherapy (anti-PD-L1 antibodies atezolizumab or durvalumab) followed by maintenance immunotherapy.
  • Despite high response rates to initial chemotherapy and radiation, more than 80% of patients relapse and die within 1 to 2 years.
  • Patients with resected SCLC, any stage, should be offered adjuvant chemotherapy (e.g., four cycles of etoposide/platinum).
  • Median survival time at relapse after first-line therapy is approximately 6 months.
  • Second-line chemotherapy (e.g., topotecan, lurbinectedin, CAV, temozolomide) can prolong survival and improve symptoms.
  • Surgical intervention is rarely considered in the management of SCLC, but there are several instances where surgery may be indicated, including in stage I disease, for mixed-histology tumors (10%-15%), for second primary tumors (often non-SCLC), and large, isolated and symptomatic brain metastases.
  • Age alone should not be a primary determinant in the decision to treat. Fit, older patients should be considered candidates for combination chemotherapy and thoracic radiation.

-- To view the remaining sections of this topic, please or --

Key Point

  • Small cell lung cancer (SCLC) represents approximately 15% of lung cancer cases.
  • SCLC is generally divided into two functional stages, limited (LS-SCLC) and extensive (ES-SCLC). Limited-stage is disease confined to a single radiation port – within one hemithorax with or without involvement of lymph nodes in the mediastinum. Extensive stage is disease beyond those confines, generally outside the chest or with contralateral chest involvement. LS-SCLC median overall survival is 20 months, 1-year survival 60%, 5-year survival 20%. ES-SCLC median overall survival is 13 months, 1-year survival 54%, 5-year survival 1%. In the 8th edition of the AJCC staging manual, TNM staging is now applied to small cell lung cancer but most clinicians continue to use the old system.
  • The standard treatment for LS-SCLC is chemotherapy (e.g. etoposide/platinum) and concurrent chest radiotherapy, followed by PCI in responding patients; this is associated with a long-term survival rate of 15% to 20%. Stage I(small tumor, node-negative) cases can be approached with surgical resection followed by adjuvant systemic chemotherapy with four cycles of cisplatin and etoposide.
  • Standard therapy for ES-SCLC is systemic chemotherapy (e.g., four cycles of etoposide/platinum) with immunotherapy (anti-PD-L1 antibodies atezolizumab or durvalumab) followed by maintenance immunotherapy.
  • Despite high response rates to initial chemotherapy and radiation, more than 80% of patients relapse and die within 1 to 2 years.
  • Patients with resected SCLC, any stage, should be offered adjuvant chemotherapy (e.g., four cycles of etoposide/platinum).
  • Median survival time at relapse after first-line therapy is approximately 6 months.
  • Second-line chemotherapy (e.g., topotecan, lurbinectedin, CAV, temozolomide) can prolong survival and improve symptoms.
  • Surgical intervention is rarely considered in the management of SCLC, but there are several instances where surgery may be indicated, including in stage I disease, for mixed-histology tumors (10%-15%), for second primary tumors (often non-SCLC), and large, isolated and symptomatic brain metastases.
  • Age alone should not be a primary determinant in the decision to treat. Fit, older patients should be considered candidates for combination chemotherapy and thoracic radiation.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: July 13, 2022